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Lung cancer is characterized by a high mortality rate probably attributable to early metastasis. Oxidative stress is
involved in development and progression of lung cancer, through cellular and molecular mechanisms which at
least in part overlap with proinflammatory pathways. Simvastatin is a statin with pleiotropic effects that can also act
as an anti-oxidant agent, and these pharmacologic properties may contribute to its potential anti-cancer activity.
Therefore, the aim of this study was to evaluate, in the human lung adenocarcinoma cell line GLC-82, the effects
of a 24-hour treatment with simvastatin on hydrogen peroxide (H2O2)-induced changes in cell viability, ERK
phosphorylation, matrix metalloproteinase (MMP) expression, innate immunity signaling, NF-κB activation and
IL-8 secretion. Cell counting was performed after trypan blue staining, cell proliferation was assessed using MTT
assay, and apoptosis was evaluated through caspase-3 activation and Tunel assay. Western blotting was used to
analyze protein extracts, and IL-8 release into cell culture supernatants was assessed by ELISA. Our results show
that simvastatin (30 μM) significantly (P <0.01) inhibited the proliferative effect of H2O2 (0.5 mM) and its stimulatory
actions on ERK1/2 phosphorylation, NF-κB activation and IL-8 production. Furthermore, simvastatin decreased
H2O2-mediated induction of the cellular expression of MMP-2 and MMP-9, as well as of several components of the
signaling complex activated by innate immune responses, including MyD88, TRAF2, TRAF6 and TRADD. In conclusion,
these findings suggest that simvastatin could play a role in prevention and treatment of lung cancer via modulation of
important proinflammatory and tumorigenic events promoted by oxidative stress.
Keywords: Lung cancer, NF-κB, Matrix metalloproteinases, Innate immunity, IL-8, SimvastatinBackground
The respiratory system is remarkably susceptible to
oxidative stress because of its peculiar anatomical and
functional properties, mainly related to the large area
exposed to the external environment. Therefore, the
cellular/tissue injury triggered by the oxidant burden
generated by air pollutants in association with cigarette
smoking plays a pivotal role in the pathogenesis of
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unless otherwise stated.including chronic obstructive pulmonary disease (COPD),
asthma, acute respiratory distress syndrome (ARDS), idio-
pathic pulmonary fibrosis (IPF), cystic fibrosis, and also
lung cancer.
In particular, inhaled oxidants such as ozone and nitro-
gen dioxide cause sequestration of inflammatory cells into
the pulmonary microcirculation, thus leading to their
accumulation within air spaces. Cigarette smoke, which
contains many oxidants and free radicals in both its gas-
eous and particulate phases [1], significantly contributes
to recruit macrophages into the airways, as well as to
increase neutrophil numbers within lung microvessels.
Once recruited and activated, macrophages, neutrophils
and eosinophils produce and release reactive oxygenLtd. This is an Open Access article distributed under the terms of the Creative
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anion (O2.
−), the latter being rapidly converted to hydro-
gen peroxide (H2O2) by superoxide dismutase (SOD) [2].
ROS may interfere with signal transduction pathways
regulating the functions of transcription factors such as
nuclear factor κB (NF-κB) and activator protein-1 (AP-1)
[3]. NF-κB and AP-1 are responsible for the coordinated
expression of several genes that control inflammation, cell
proliferation and apoptosis. Within this context a key role
is played by mitogen-activated protein kinases (MAPK),
whose targets are mainly represented by nuclear transcrip-
tion factors, also including those involved in oxidative
stress. In particular, the ERK1/2 subgroup of MAPK is
activated by a MAPK kinase kinase named Raf (most
commonly Raf-1), whose activation in turn requires the
GTP-bound form of Ras family proteins [4]. Once acti-
vated, Raf-1 phosphorylates the MAPK kinases MEK1 and
MEK2, that finally stimulate ERK1 and ERK2.
Airborne pollutants and cigarette smoke can induce
the bronchial epithelium to acquire a proinflammatory
phenotype, characterized by an increased production of
autacoids, cytokines, and chemokines [5]. Oxidant-induced
phenotypic changes may thus significantly contribute to the
key pathogenic role played by bronchial epithelial cells in
inflammatory airway disorders such as asthma and COPD.
Moreover, ROS may also contribute via several different
signalling pathways, including MAPK activation, to devel-
opment and progression of lung cancer [6].
Lung cancer is the leading cause of neoplastic death
worldwide. More than 80% of lung cancer cases belong
to the non small cell lung cancer (NSCLC) type, which
can be further subdivided into adenocarcinoma (approxi-
mately 40% of all NSCLCs), squamous cell carcinoma and
large cell carcinoma [7]. The metastatic potential of
NSCLC strongly correlates with the cellular expression of
matrix metalloproteinases (MMPs), which are regulated
by NF-κB and by the metastasis suppressor RECK (re-
version-inducing-cysteine-rich protein with kazal motif )
[8,9]. Moreover, the complex cellular and molecular
mechanisms underlying the development and progression
of NSCLC are also significantly affected by the innate im-
mune system [6]. Indeed, the latter represents the first line
of defense against noxious agents such as ROS, which can
damage the airway epithelium.
The poor survival rate of patients with NSCLC is
mostly due to its high metastatic potential and also to a
relative drug resistance [7]. Therefore, new and more
effective pharmacological treatments for NSCLC are
strongly needed. In this regard, increasing attention is
currently being paid to statins because of their capabil-
ity of inhibiting 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase, which is the rate limiting
enzyme within the mevalonate pathway. Hence, by
blocking the synthesis of mevalonate and its isoprenoidderivatives farnesyl pyrophosphate (FPP) and geranyl
geranyl pyrophosphate (GGPP), statins also prevent
prenylation-dependent activation of oncogenic Ras pro-
teins [10]. Indeed, statins may have a cytostatic effect on
cancer cells, and can prolong the survival of cancer patients
[11]. They also act as anti-oxidant, anti-inflammatory and
anti-angiogenic factors, and could therefore prevent or in-
hibit cancer cell growth [12]. Furthermore, we have recently
shown that simvastatin is able to induce a decrease in cell
proliferation and a significant increase of apoptosis in
human NSCLC cell cultures [13], as well as to modulate
Ras, MMP-2/9 and NF-κB activity in pulmonary neoplas-
tic tissues obtained from patients undergoing therapeutic
surgery for lung cancer [14].
On the basis of the above mentioned considerations,
the aim of our present study has been to investigate, in the
human lung adenocarcinoma cell line GLC-82 exposed to
H2O2, the effects of simvastatin on cell viability and apop-
tosis, ERK phosphorylation, MMP2/9 and RECK protein
expression, NF-κB nuclear content and interleukin-8 (IL-8)
secretion. Moreover, we also assessed the effects of simva-
statin on H2O2-induced changes in the expression of some
important proteins of the signaling network underlying in-
nate immune responses, including MyD88, tumor necrosis
factor (TNF) receptor-associated factors (TRAF)2/6, and




The anti-caspase-3 monoclonal antibody E83-77 was
purchased from Abcam (Cambridge, UK). Trypan blue
was purchased from Sigma (St. Louis, MO, USA). Anti-
phospho-ERK1/2, anti-NF-κB-p65, anti-RECK, anti-MyD88,
anti-TRAF2, anti-TRADD, anti-TRAF6, anti-MMP2 and
anti-MMP9 monoclonal antibodies were purchased from
New England Biolabs (Beverly, MA, USA); an anti-(total)-
ERK1/2 polyclonal antibody was commercially provided
by Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
Purified crystalline powders of simvastatin were commer-
cially obtained from Sigma (St. Louis, MO, USA), and then
dissolved into refrigerated and light-protected DMSO stock
solution.
Culture and treatment of human lung cancer cells
GLC-82, a human lung adenocarcinoma cell line [13],
was cultured at 37°C, 5% CO2, in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FCS,
penicillin 100 U/ml, streptomycin 100 μg/ml, and
amphotericin B 25 μg/ml in a humidified 5% CO2 at-
mosphere. For each treatment, cells were plated in a
100-mm polystyrene dish (Falcon, Becton-Dickinson,
Lincoln Park, NJ, USA) and ten ml of supplemented
DMEM were then added. When GLC-82 cells grew to
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to H2O2 (0.5 mM) and then cells were or not exposed
for 24 hour to simvastatin (30 μM). The medium was
not changed after treatment. The solvent employed to
dissolve this drug was used as a control. After this
period, the medium was removed for IL-8 assessment
(see later), and cells were processed for protein extrac-
tion and immunoblotting.
Cell viability and proliferation
Cell viability was assessed by light microscopy and dye
exclusion, using Trypan blue. Cell numbers were evalu-
ated by direct counting using a hemocytometer, in agree-
ment with our previous reports [15-17]. Cell proliferation
was investigated by 3-[4,5-dimethylthiazol-2-yl]-2,5 diphe-
nyl tetrazolium bromide (MTT) assay, based on the con-
version by mitochondrial dehydrogenases of the substrate
containing a tetrazolium ring into blue formazan, detect-
able spectrophotometrically. The level of blue formazan
was then used as an indirect index of cell density. Briefly,
after treatment with either H2O2 and/or simvastatin, cells
were exposed to MTT (5 μg/mL) for 150 min at 37°C.
The medium was then removed and cells were solubilized
with acidified isopropanol and 2% sodium dodecyl sulfate
(SDS). After complete solubilization, presence of blue for-
mazan was evaluated spectrophotometrically at a refer-
ence wavelength of 650 nm. All experiments were carried
out in triplicate.
Protein extraction and immunoblot analysis
Following treatment with simvastatin, cells were lysed
for Western blotting in radioimmunoprecipitation assay
(RIPA) buffer, as previously described [18]. Moreover,
nuclear extracts were obtained using the NE-PER cell
fractionation kit (Thermo Scientific, Rockford, IL,
USA). Briefly, whole cell lysates or nuclear proteins
were then separated on a 12.5% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred onto polyvinylidene difluoride (PVDF) mem-
branes (Amersham Pharmacia, Little Chalfont, UK). Im-
munoblotting was performed using the above mentioned
monoclonal antibodies. After being “stripped”, membranes
were re-probed with a polyclonal antibody against total
(phosphorylated and unphosphorylated) ERK1/2 proteins.
Antibody binding was visualized by enhanced chemilu-
minescence (ECL-Plus; Amersham Pharmacia); intensities
of experimental bands were analyzed by computer-assisted
densitometry and expressed as arbitrary units, as previously
described [19]. These experiments were performed in
triplicate.
TUNEL assay
TdT (terminal deoxynucleotidyl transferase)-mediated
dUTP nick-end labeling (TUNEL) assay was performedin agreement with our previous reports [13]. Briefly, cells
were plated on 24 9 24 mm cover slips (Carlo Erba
Reagenti, Milan, Italy) and placed in six-well microtitre
plates (Corning Incorporated, Corning, NY, USA) in
DMEM supplemented with 10% FCS, penicillin 100 U/ml,
streptomycin 100 mg/ml, and fungizone 25 mg/ml; 24 h
after plating, when cells had reached 50–60% confluence,
they were treated or not with H2O2 (0.5 mM) for 2 hours,
and then were exposed or not to simvastatin (30 μM) for
24 hours; the incubation medium was not changed. Fol-
lowing treatment, TUNEL assay was performed using
MEBSTAIN Apoptosis TUNEL Kit Direct (MBL, Woburn,
MA, USA), strictly following instructions provided by the
manufacturer. Photographs were acquired using a Leica
GRDM confocal microscope (Leica, Wetzlar, Germany).
IL-8 secretion
Culture supernatants were collected and assayed for IL-8
by ELISA using a commercially available kit (Peli-Kine kit;
Eurogenetics, Hampton, UK; sensitivity limit, 1 pg/ml), ac-
cording to manufacturer’s protocol. These experiments
were performed in triplicate.
Statistical analysis
All data are expressed as mean ± standard error (SEM).
Statistical evaluation of the results was performed by
analysis of variance (ANOVA). Differences identified by
ANOVA were pinpointed by unpaired Student’s t test.
The threshold of statistical significance was set at P <0.05.
Results
Cell viability
MTT assay detected an increase in cell number in cells
pretreated with H2O2 (0.5 mM). In contrast, a 24 hours
treatment with simvastatin (30 μM) was able to significantly
decrease (P < 0.01) the cell number with respect to both
control and pretreatment with H2O2. Therefore, simva-
statin was able to modify normal growth cell, as well as to
change the effect of H2O2 on cell proliferation (Figure 1).
Caspase-3 activation
Human GLC-82 cells were characterized by relatively
low levels of caspase-3 activation, detected at baseline
conditions as well as after exposure to H2O2 (0.5 mM)
and after simvastatin treatment. Simvastatin (30 μM)
significantly increased (P <0.01) the expression of active
caspase-3 (Figure 2).
TUNEL assay
H2O2 (0.5 mM) did not modify the number of TUNEL-
positive cells, with respect to untreated cells (control).
By contrast, in the presence of H2O2, simvastatin (30 μM)
significantly (P < 0.01) increased (of about 30%) the num-
ber of TUNEL-positive cells (Figure 3).
Figure 1 Cell viability. Effects of hydrogen peroxide (H2O2) on GLC-82 cell proliferation in the presence or absence of a 24 hours treatment with
simvastatin (30 μM). Cell proliferation was assessed by MTT assay. *P < 0.01 (H2O2 vs control); #P <0.01 (H2O2 + simvastatin and simvastatin vs
H2O2). Data represent the mean of three experiments.
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Exposure of GLC-82 cells for 2 hours to H2O2 caused a sig-
nificant (P < 0.01) increase in ERK1/2 phosphorylation; this
effect was significantly inhibited in presence of a 24 hours
treatment with simvastatin (P < 0.01) (Figure 4). Simvastatin
(30 μM) induced a significant decrease (P < 0.01) of p-ERK
expression. Both H2O2 and simvastatin exerted their ef-
fects uniquely on phosphorylation-dependent activation
of ERK1/2, without affecting its total expression, asFigure 2 Caspase-3 activation. Western blot evaluation of caspase-3 expre
treatment with simvastatin. Data represent the mean ± SEM of three experimedemonstrated by the unchanged binding patterns of the
anti-(total)ERK polyclonal antibody (data not shown).
Matrix metalloproteinase expression
H2O2 induced a significant (P <0.01) increase in MMP-2
and MMP-9 expression. These effects were reverted by
treatment with simvastatin (Figure 5). Moreover, simva-
statin induced a significant decrease of both MMP-2
and MMP-9 baseline expression.ssion with and without H2O2,in the presence or absence of a 24 hours
nts. **P <0.01. #P <0.01 (H2O2 + simvastatin and simvastatin vs H2O2).
Figure 3 TdT (terminal deoxynucleotidyl transferase)-mediated dUTP nick-end labeling (TUNEL) assay of GLC cells exposed or not to
H2O2 (0.5 mM) for 2 hours, and then to simvastatin (30 μM) for 24 hours. ** P < 0.01 H2O2 + Simvastatin vs non treated cells (Cnt) and vs
cells exposed to H2O2 (0.5 mM) alone.
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H2O2 induced a significant (P <0.01) decrease in RECK
expression, whereas treatment with simvastatin significantly
(P <0.01) enhanced RECK cellular content (Figure 6).NF-κB nuclear content
H2O2 elicited a significant (P <0.01) increase in NF-κB
nuclear levels, and this effect was significantly inhibited
by treatment with simvastatin (P <0.01) (Figure 7).Figure 4 ERK phosphorylation. Western blot evaluation of phosphorylated
and in the presence or absence of 24 hours treatment with simvastatin.Data r
control); #P < 0.01 (H2O2 + simvastatin and simvastatin vs H2O2).MyD88 and TRAF6 expression
H2O2 induced a significant (P < 0.01) increase in MyD88
and TRAF6 expression, and these effects were significantly
(P <0.01) inhibited by treatment with simvastatin (Figure 8).TRADD and TRAF2 expression
H2O2 caused a significant (P <0.01) increase in TRADD
and TRAF2 expression. These effects were significantly
(P <0.01) inhibited by treatment with simvastatin (Figure 9).ERK 1/2 (phospho-ERK) expression following or not H2O2 administration,
epresent the mean ± SEM of three experiments. *P < 0.01 (H2O2 vs
Figure 5 Matrix metalloproteinase expression. Western blot evaluation of MMP-2 (upper panel) and MMP-9 (lower panel) expression following
or not H2O2 administration, and in the presence or absence of 24 hours treatment with simvastatin. Data represent the mean ± SEM of three
experiments *P < 0.01 (H2O2 vs control); #P < 0.01 (H2O2 + simvastatin and simvastatin vs H2O2).
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H2O2 elicited a significant (P <0.01) increase in IL-8
secretion, which was significantly (P <0.01) prevented by
pretreatment with simvastatin (Figure 10).
Discussion
In this study we evaluated the effects of simvastatin on
lung adenocarcinoma GLC-82 cells, exposed to hydrogen
peroxide (H2O2). Interestingly, oxidants are capable of
exerting a tumorigenic action via molecular mechanisms
which at least in part are also activated by proinflamma-
tory pathways [20,21], and several authors have shown
that both oxidative stress and inflammation are involved
in the development and progression of cancer [22].
Therefore, we focused our attention on several cellular
events triggered by oxidative stress. Within such a research
context, it is noteworthy to point out that simvastatinwas able to induce a comprehensive inhibition of many
phenomena related to lung cancer.
In this regard, Manfredini et al. have previously reported
that simvastatin is able to modulate oxidative DNA dam-
age [23], and we also showed that simvastatin significantly
decreased H2O2-induced cell proliferation rate, probably
through inhibition of Ras-dependent phosphorylative acti-
vation of the ERK1/2 subgroup of MAPKs [13]. In fact,
H2O2 dramatically enhanced ERK phosphorylation, and
such a stimulatory action was markedly reduced by simva-
statin. This implies that simvastatin affects ERK function
by inhibiting mevalonate-dependent post-translational
prenylation of Ras, thus impairing the sequential activa-
tion of the Ras/Raf/MEK/ERK signalling cascade [24].
Therefore, this mechanism may be also involved in the
observed pro-apoptotic action of simvastatin, documented
by the increased expression of active caspase-3 [25].
Figure 6 RECK expression. Western blot evaluation of RECK expression following or not H2O2 administration, and in the presence or absence
of 24 hours treatment with simvastatin. Data represent the mean ± SEM of three experiments. *P < 0.01 (H2O2 vs control); #P < 0.01 (H2O2 +
simvastatin vs H2O2).
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and pro-apoptotic effects of simvastatin were also paralleled
by a drug-induced up-regulation of RECK protein, which
plays a pivotal role in inhibiting matrix metalloproteinases.
MMP-2 and MMP-9 are responsible for extracellular matrix
degradation, and for the consequent neo-angiogenesis,
vascular invasion and metastatic potential that characterize
malignant tumours [26-28]. Indeed, in many cancers RECKFigure 7 NF-kB nuclear content. Western blot evaluation of NF-κB nuclea
presence or absence of 24 hours treatment with simvastatin. Data represen
#P < 0.01 (H2O2 + simvastatin and simvastatin vs H2O2).down-regulation is associated with high levels of MMP-9
[9]. Otherwise, preservation of RECK expression in some
neoplasms correlates with a relatively low microvascular
density as well as with a better prognosis, due to a decreased
tendency to metastatic invasion [29]. Consistently with these
considerations, our results show that H2O2 down-regulated
RECK in GLC-82 cells, whereas simvastatin restored its ex-
pression. Moreover, H2O2 enhanced MMP-2 and MMP-9r levels in GLC-82 cells following or not H2O2 administration, in the
t the mean ± s.e.m. of three experiments. *P < 0.01 (H2O2 vs control);
Figure 8 MyD88 and TRAF6 expression. Western blot evaluation of MyD88 (upper panel) and TRAF6 (lower panel) expression followingH2O2
administration, in the presence or absence of 24 hours treatment with simvastatin. Data represent the mean ± SEM of three experiments.
*P <0.01 (H2O2 vs control); #P <0.01 (H2O2 + simvastatin vs H2O2).
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prevented by simvastatin.
Other important observations reported in the present
study refer to further aspects of signal transduction. In
particular, our data demonstrate that the noxious effects
of oxidative stress on human lung adenocarcinoma cell
lines, as well as the potential anti-cancer activity of
statins, are also attributable to interferences with the
signalling pathways linked to innate immunity [30]. In
this regard, it is remarkable that H2O2 induced the
expression of MyD88, a key molecular component of the
intracellular signalling machinery activated by Toll-like
receptors (TLRs), and once again simvastatin abrogated
such effect. MyD88 associates with TLRs; upon stimu-
lation, MyD88 recruits IL-1 receptor-associated kinase
(IRAK) to TLRs via interaction of the death domains ofboth molecules [31]. IRAK is activated by phosphoryl-
ation and then associates with tumor necrosis factor
(TNF) receptor-associated factor 6 (TRAF6). Similarly
to MyD88, the opposite actions of H2O2 and simvastatin
translated into significant increases and decreases in
TRAF6 expression, respectively. Therefore, on the basis
of this experimental work, we canspeculate that oxida-
tive stress triggers a particular type of tissue injury
which is sensed by the surveillance network of innate
immunity via TLR stimulation. In fact, it has been dem-
onstrated that H2O2 can prime the responsiveness of
the innate immune system through a recruitment of
TLRs to cell plasma membrane [32]. However, this
chain of molecular events, including the essential step
of MyD88 activation, ultimately culminates in the down-
stream involvement of the transcription factor NF-κB,
Figure 9 TRADD and TRAF2 expression. Western blot evaluation of TRADD (upper panel) and TRAF2 (lower panel) expression following or not
H2O2 administration, in the presence or absence of 24 hours treatment with simvastatin . Data represent the mean ± SEM of three experiments.
*P <0.01 (H2O2 vs control); #P <0.01 (H2O2 + simvastatin and simvastatin vs H2O2).
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flammatory attitudes of oxidative stress. It can thus be
argued that, by interrupting such complex molecular
cascades, statins can have relevant anti-cancer and
anti-inflammatory properties.
Other important components of the macromolecular
complex associated with TNF receptor superfamily, whose
stimulation leads to NF-κB activation, include TRADD
and TRAF2 proteins [33]. Here it is shown that both
TRADD and TRAF2 were susceptible to up-regulation in-
duced by H2O2, and this effect was prevented by simva-
statin. Because the above mentioned signaling pathways
converge towards NF-κB activation, it was not surprising
to detect in GCL-82 cells, as a result of their exposure to
H2O2, an increased nuclear content of NF-κB. Indeed,nuclear translocation of this transcription factor is the
essential step underlying its activation. Consistently with
the overall experimental design of this study, it was well
expected to find the observed decrease of NF-κB nuclear
levels elicited by simvastatin.
Moreover, a further evidence of the opposite actions
of H2O2 and simvastatin was found by analyzing, in
GLC-82 cell culture supernatants, the changes refer-
ring to the concentrations of IL-8, which acts as a
powerful chemoattractant for neutrophils [34]. In
particular, IL-8 secretion was up-regulated and down-
regulated by H2O2 and simvastatin, respectively. Indeed,
this proinflammatory chemokine is encoded by a gene
targeted by the transcriptional stimulatory activity of
NF-κB [35].
Figure 10 IL-8 secretion. ELISA evaluation of IL-8 secretion in GLC-82 cell culture supernatants in the presence or absence of exposure to H2O2
and with or withouta 24 hours treatment with simvastatin. Data represent the mean ± SEM of three experiments. *P <0.01 (H2O2 vs control);
#P <0.01 (H2O2 + simvastatin and simvastatin vs H2O2).
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gest the existence of a tight cross-talk involving the
proliferative, metastatic and proinflammatory mechanisms
activated by oxidative stress in GLC-82 cells. Moreover,
our data clearly demonstrate that in this lung adenocar-
cinoma cell line simvastatin can effectively interfere with
the complex signal transduction networks underlying such
mechanisms. These findings confirm and further extend
our previous data obtained in the same GLC-82 cell line,
showing that simvastatin was able to significantly decrease
cell proliferation and increase apoptosis via inhibition of
the ERK1/2 subgroup of MAPKs [13].
With regard to MMP-2 and MMP-9, it is well known
that these enzymes promote cancer progression through
extracellular matrix and basement membrane degradation,
resulting in the exposure of cryptic locations linked to
invasion, metastasis and angiogenesis. The 5′ flanking re-
gions of the MMP-2 and MMP-9 genes contain several
functional regulatory motifs that bind transcription factors
such as NF-κB [36,37]. Through the interactions between
NF-κB and its DNA binding sites, various agents including
growth factors and cytokines are able to regulate MMP
expression. Hence, the coordinated inhibitory effects of
simvastatin on MMP2/9 expression and NF-κB activation
imply the involvement of HMG-CoA reductase pathway
in the process of metastatic invasion related to NF-κB and
MMP activity. In fact, cancer cells usually express high
levels of HMG-CoA reductase, which appear to be re-
quired by NSCLC cells to satisfy their increased need for
isoprenoids and lipids.
Thus, by blocking Ras prenylation, simvastatin could
interfere with NF-κB-dependent signaling networks
responsible not only for MMP expression, but also forIL-8 synthesis. Indeed, it is reasonable to infer that, by
inhibiting Ras/Raf-induced phosphorylative activation of
MAPKs, simvastatin may be able to prevent IL-8 pro-
duction elicited in GLC-82 cells by NF-κB activation due
to oxidative stress.
Conclusion
In conclusion, our results show that simvastatin is able to
inhibit the effects of H2O2 on lung cancer cells, suggesting
that simvastatin is able to induce an antiproliferative, pro-
apoptotic and antinflammatory effects in presence of a
pro-inflammatory mediator. These data could support the
role of simvastatin in the prevention of cancer and lung
inflammatory disease (i.e. chronic obstructive pulmonary
diseases). In fact to date no definitive reports have been
published regarding these diseases [38,39]. However, in
order to validate these preliminary observations further
studies are needed, especially including controlled clinical
trials.
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